enGene Holdings Inc. (NASDAQ:ENGN) Receives $29.78 Consensus Price Target from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been assigned an average recommendation of “Buy” from the eleven ratings firms that are covering the stock, Marketbeat reports. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $29.78.

A number of brokerages have issued reports on ENGN. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a research note on Monday, December 23rd. Raymond James started coverage on enGene in a research note on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price target on the stock. HC Wainwright began coverage on shares of enGene in a report on Monday, December 23rd. They set a “buy” rating and a $25.00 target price for the company. Finally, Citizens Jmp upgraded enGene to a “strong-buy” rating in a research note on Monday, November 18th.

enGene Stock Performance

Shares of NASDAQ ENGN opened at $6.77 on Friday. enGene has a one year low of $4.42 and a one year high of $18.40. The firm has a market capitalization of $299.37 million, a price-to-earnings ratio of -11.67 and a beta of -0.65. The business has a fifty day simple moving average of $7.36 and a 200 day simple moving average of $7.50. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. Sell-side analysts expect that enGene will post -1.57 EPS for the current year.

Institutional Investors Weigh In On enGene

A number of institutional investors have recently made changes to their positions in ENGN. Wolverine Asset Management LLC acquired a new position in shares of enGene during the 3rd quarter worth approximately $37,000. Point72 Asset Management L.P. lifted its holdings in shares of enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after acquiring an additional 619,100 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after buying an additional 389,918 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.